/
DCF Valuation
Base-case fair value
$5.23
Intrinsic $6.98 · 25% MOS
Current price: $10.61
Base-case summary
Our base-case DCF for Zevra Therapeutics, Inc. (ZVRA) projects 10 years of free cash flow growth at 3.0% for years 1–5 and 1.5% for years 6–10, anchored to 3.0% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $12M in trailing free cash flow, this produces an intrinsic value of $6.98 per share. A 25% safety margin gives a fair value of $5.23, suggesting the stock is currently 51% overvalued against the $10.61 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$12M
Cash & equivalents
$201M
Total debt
$1M
Shares outstanding
60M